ATE347557T1 - Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung - Google Patents

Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung

Info

Publication number
ATE347557T1
ATE347557T1 AT01914191T AT01914191T ATE347557T1 AT E347557 T1 ATE347557 T1 AT E347557T1 AT 01914191 T AT01914191 T AT 01914191T AT 01914191 T AT01914191 T AT 01914191T AT E347557 T1 ATE347557 T1 AT E347557T1
Authority
AT
Austria
Prior art keywords
fluorisoquinoline
derivatives
production
pde
copd
Prior art date
Application number
AT01914191T
Other languages
English (en)
Inventor
Yasuhiko Kawano
Tatsumi Matsumoto
Osamu Uchikawa
Nobuhiro Fujii
Naoki Tarui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE347557T1 publication Critical patent/ATE347557T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01914191T 2000-03-23 2001-03-22 Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung ATE347557T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000087121 2000-03-23

Publications (1)

Publication Number Publication Date
ATE347557T1 true ATE347557T1 (de) 2006-12-15

Family

ID=18603181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914191T ATE347557T1 (de) 2000-03-23 2001-03-22 Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung

Country Status (7)

Country Link
US (1) US6924292B2 (de)
EP (1) EP1270577B1 (de)
AT (1) ATE347557T1 (de)
AU (1) AU2001239550A1 (de)
CA (1) CA2404226A1 (de)
DE (1) DE60125026T2 (de)
WO (1) WO2001070746A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
WO2003000697A1 (en) * 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Furoisoquinoline derivative, process for producing the same, and use
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
WO2003035650A1 (en) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
AU2003281691A1 (en) * 2002-07-26 2004-02-16 Takeda Pharmaceutical Company Limited Furoisoquinoline derivative and use thereof
AU2003263216A1 (en) * 2002-08-17 2004-03-11 Nycomed Gmbh Benzonaphthyridines with PDE 3/4 inhibiting activity
CA2495597A1 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
SI1620429T1 (sl) 2003-04-11 2009-08-31 Glenmark Pharmaceuticals Sa Nove heterociklične spojine, uporabne za zdravljenje vnetnih in alergijskih motenj: postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MX2007004400A (es) 2004-10-13 2007-06-19 Glenmark Pharmaceuticals Sa Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.
UA88795C2 (ru) 2004-12-17 2009-11-25 Гленмарк Фармасьютікалс С.А. Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
CN102600144A (zh) 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070048388A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2296653B1 (de) 2008-06-03 2016-01-27 Intermune, Inc. Verbindungen und verfahren zur behandlung von entzündungserkrankungen und fibrotischen erkrankungen
CN104784180A (zh) * 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756105A (fr) * 1969-09-15 1971-03-15 Geigy Ag J R Nouveaux acides carboxyliques heterocycliques et medicaments contenant de tels acides
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
JPH07121933B2 (ja) * 1988-03-28 1995-12-25 キッセイ薬品工業株式会社 ジヒドロベンゾフラノン誘導体
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
PT828728E (pt) * 1995-05-18 2003-06-30 Altana Pharma Ag Di-hidrobenzofuranos de fenilo
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification

Also Published As

Publication number Publication date
EP1270577A4 (de) 2003-09-17
WO2001070746A1 (en) 2001-09-27
DE60125026D1 (de) 2007-01-18
DE60125026T2 (de) 2007-06-28
US6924292B2 (en) 2005-08-02
CA2404226A1 (en) 2001-09-27
US20040092582A1 (en) 2004-05-13
EP1270577B1 (de) 2006-12-06
AU2001239550A1 (en) 2001-10-03
EP1270577A1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
EP1270577A4 (de) Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
WO2004024728A3 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
WO2004046112A3 (en) 3-amino-piperidine derivatives and processes for their preparation
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
NO20042378L (no) A2B-adenosinreseptorantagonister
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
CY1106969T1 (el) Αναστολεις dpp-iv
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
WO2001090071A3 (de) Substituierte iminoazine als herbizide
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
WO2006018718A3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
WO2004020430A3 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
WO2003041647A3 (en) Synthesis and purification of valacyclovir
WO2005033066A3 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique sanofi-synthelabo
DE60204463D1 (de) Substituierte 8-Arylchinoline als PDE4-Hemmer
WO2004082629A3 (en) Novel cyclosporins
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
EA200100906A1 (ru) Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких
WO2007010356A8 (en) Process for the preparation of sulfonamide derivatives
WO2005079496A3 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2003093278A3 (en) Process for the preparation of ceftiofur acid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties